{
  "main_header": {
    "sid": 849091,
    "name": "Archit Organosys",
    "stock_name": "Archit Organosys",
    "full_name": "Archit Organosys Ltd",
    "name_url": "stocks-analysis/archit-organosys",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "42.88",
    "chg": -1.44,
    "chgp": "-3.25%",
    "dir": -1,
    "prev_price": "44.32",
    "mcapval": "92.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524640,
    "symbol": "",
    "ind_name": "Commodity Chemicals",
    "ind_code": 11,
    "indexname": "",
    "isin": "INE078I01011",
    "curr_date": "Dec 17",
    "curr_time": "",
    "bse_nse_vol": "8.52 k",
    "exc_status": "Active",
    "traded_date": "Dec 17, 2025",
    "traded_date_str": "2025 12 17",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/archit-organosys-849091-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Archit Organosys Sees Revision in Market Evaluation Amidst Challenging Commodity Chemicals Sector",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/archit-organosys-downgraded-to-sell-by-marketsmojo-amid-weak-fundamentals-3749838",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/ArchitOrganosys_mojoScore_3749838.png",
        "date": "2025-12-06 10:10:23",
        "description": "Archit Organosys, a microcap player in the commodity chemicals sector, has undergone a revision in its market evaluation reflecting shifts in its fundamental and technical outlook. This adjustment follows a period marked by subdued returns and a cautious market stance, underscoring the complexities faced by smaller companies in this segment."
      },
      {
        "title": "Why is Archit Organosys falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-archit-organosys-fallingrising-3736108",
        "imagepath": "",
        "date": "2025-11-29 00:42:50",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Short-Term Gains Amidst Broader Challenges</strong></p>\n<p>Despite the recent rise, Archit Organosys has struggled to keep pace with the broader market. Over the past week, the stock declined by 1.02%, while the Sensex advanced by 0.56%. The divergence is more pronounced over longer periods, with the stock falling 8.77% in the last month compared to a 1.27% gain in the Sensex. Year-to-date, Archit Organosys is down 12.72%, whereas the benchmark index has appreciated by 9.68%. This trend extends further back, with the stock underperforming the Sensex by a wide margin over one, three, and five-year periods.</p>\n<p>However, the recent three-day rally, which has delivered a cumulative return of 6.92%, indicates a potential shift in investor sentiment. This short-term strength is supported by ris..."
      },
      {
        "title": "Archit Organosys Q2 FY26: Profitability Under Pressure as Margins Collapse",
        "link": "https://www.marketsmojo.com/news/result-analysis/archit-organosys-q2-fy26-profitability-under-pressure-as-margins-collapse-3713377",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ArchitOrganosys_quaterlyResult_3713377.png",
        "date": "2025-11-14 09:36:16",
        "description": "Archit Organosys Ltd., a micro-cap commodity chemicals manufacturer, is navigating turbulent waters as its latest quarterly results reveal a sharp deterioration in operational efficiency. The company, with a market capitalisation of ₹92.00 crores, faces mounting challenges despite reporting improved topline growth in recent quarters."
      },
      {
        "title": "Is Archit Organosys overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-archit-organosys-overvalued-or-undervalued-3700240",
        "imagepath": "",
        "date": "2025-11-14 08:11:46",
        "description": "As of 13 November 2025, Archit Organosys' valuation grade has moved from attractive to fair. The company appears to be overvalued based on its current metrics. Notable ratios include a PE ratio of 147.70, an EV to EBITDA of 18.19, and a PEG ratio of 0.01, which suggests a significant disparity in growth expectations relative to its price.\n\nIn comparison to peers, Archit Organosys' PE ratio is substantially higher than that of Godrej Industries at 37.09, which is rated attractive, and Aarti Industries at 53.04, also rated fair. The company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -6.00% compared to the Sensex's 8.11%, further reinforcing the notion that Archit Organosys is currently overvalued...."
      },
      {
        "title": "How has been the historical performance of Archit Organosys?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-archit-organosys-3699047",
        "imagepath": "",
        "date": "2025-11-13 23:21:18",
        "description": "Answer:\nThe historical performance of Archit Organosys shows a declining trend in net sales and profits over the past few years.\n\nBreakdown:\nArchit Organosys reported net sales of 113.19 Cr in March 2024, a decrease from 127.78 Cr in March 2023 and 137.90 Cr in March 2022. The total operating income mirrored this decline, remaining at 113.19 Cr in March 2024 compared to 127.78 Cr in the previous year. The total expenditure, excluding depreciation, also decreased to 106.45 Cr in March 2024 from 108.90 Cr in March 2023. Operating profit (PBDIT) fell significantly to 9.18 Cr in March 2024 from 20.74 Cr in March 2023, reflecting a decrease in the operating profit margin from 14.78% to 5.95%. Profit before tax dropped to 4.32 Cr in March 2024, down from 15.36 Cr in March 2023, leading to a profit after tax of 3.28 Cr compared to 11.35 Cr the previous year. The earnings per share also declined to 1.6 in March 202..."
      },
      {
        "title": "Why is Archit Organosys falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-archit-organosys-fallingrising-3690791",
        "imagepath": "",
        "date": "2025-11-11 22:04:41",
        "description": "As of 11-Nov, Archit Organosys Ltd's stock price is currently at 45.48, reflecting an increase of 0.2, or 0.44%. The stock has experienced a trend reversal, gaining after two consecutive days of decline. It is trading above its 100-day and 200-day moving averages, but below its 5-day, 20-day, and 50-day moving averages. Additionally, there has been a notable increase in investor participation, with delivery volume rising by 13.73% compared to the 5-day average. However, the stock has shown a negative performance over the past week, month, and year, with declines of 1.32%, 1.83%, and 2.99%, respectively, against a backdrop of positive returns from the benchmark Sensex during the same periods. The positive and negative factors dashboard is unavailable, which limits further insights into specific influences on the stock's recent movements.\n\nBroader Market Context: In the short term, Archit Organosys has underp..."
      },
      {
        "title": "When is the next results date for Archit Organosys?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-archit-organosys-3681106",
        "imagepath": "",
        "date": "2025-11-07 23:18:48",
        "description": "The next results date for Archit Organosys is scheduled for 13 November 2025...."
      },
      {
        "title": "How has been the historical performance of Archit Organosys?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-archit-organosys-3668005",
        "imagepath": "",
        "date": "2025-11-03 22:47:04",
        "description": "Answer:\nThe historical performance of Archit Organosys shows a decline in net sales and profits over the years, particularly from March 2022 to March 2024.\n\nBreakdown:\nArchit Organosys reported net sales of 113.19 Cr in March 2024, down from 127.78 Cr in March 2023 and 137.90 Cr in March 2022, indicating a consistent decrease in revenue. The total operating income mirrored this trend, remaining at 113.19 Cr in March 2024, compared to 127.78 Cr in the previous year. The total expenditure, excluding depreciation, also decreased to 106.45 Cr in March 2024 from 108.90 Cr in March 2023. Operating profit (PBDIT) fell significantly to 9.18 Cr in March 2024 from 20.74 Cr in March 2023, reflecting a declining operating profit margin which dropped to 5.95% in March 2024 from 14.78% the previous year. Profit before tax decreased to 4.32 Cr in March 2024, down from 15.36 Cr in March 2023, leading to a profit after tax ..."
      },
      {
        "title": "Is Archit Organosys overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-archit-organosys-overvalued-or-undervalued-3660287",
        "imagepath": "",
        "date": "2025-10-31 08:10:20",
        "description": "As of 30 October 2025, Archit Organosys has moved from a fair to an attractive valuation grade. The company is currently considered overvalued based on its high PE ratio of 150.72, an EV to EBIT of 105.73, and a PEG ratio of 0.01, indicating that the stock price does not align well with its earnings growth potential. \n\nIn comparison to its peers, Archit Organosys stands out with a significantly higher PE ratio than Godrej Industries, which has a PE of 36.66 and is also rated attractive. Meanwhile, Solar Industries, classified as very expensive, has a PE of 99.55. Despite a recent decline in stock performance relative to the Sensex, with a year-to-date return of -4.08% compared to the Sensex's 8.02%, the valuation metrics suggest that Archit Organosys is not justified at its current price level...."
      }
    ],
    "total": 106,
    "sid": "849091",
    "stock_news_url": "https://www.marketsmojo.com/news/archit-organosys-849091"
  },
  "announcements": [
    {
      "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
      "datetime": "15-Dec-2025",
      "details": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Suchit Amin",
      "source": "BSE"
    },
    {
      "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
      "datetime": "15-Dec-2025",
      "details": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Suchit Amin",
      "source": "BSE"
    },
    {
      "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
      "datetime": "12-Dec-2025",
      "details": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Suchit Kandarp Amin & PACs",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Archit Organosys Ltd has declared <strong>5%</strong> dividend, ex-date: 22 Sep 25",
          "dt": "2025-09-22",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Archit Organosys Ltd has announced <strong>2:1</strong> rights issue, ex-date: 09 Feb 17",
          "dt": "2017-02-09",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

Archit Organosys Sees Revision in Market Evaluation Amidst Challenging Commodity Chemicals Sector

2025-12-06 10:10:23

Archit Organosys, a microcap player in the commodity chemicals sector, has undergone a revision in its market evaluation reflecting shifts in its fundamental and technical outlook. This adjustment follows a period marked by subdued returns and a cautious market stance, underscoring the complexities faced by smaller companies in this segment.

Read More

Why is Archit Organosys falling/rising?

2025-11-29 00:42:50

Short-Term Gains Amidst Broader Challenges

Despite the recent rise, Archit Organosys has struggled to keep pace with the broader market. Over the past week, the stock declined by 1.02%, while the Sensex advanced by 0.56%. The divergence is more pronounced over longer periods, with the stock falling 8.77% in the last month compared to a 1.27% gain in the Sensex. Year-to-date, Archit Organosys is down 12.72%, whereas the benchmark index has appreciated by 9.68%. This trend extends further back, with the stock underperforming the Sensex by a wide margin over one, three, and five-year periods.

However, the recent three-day rally, which has delivered a cumulative return of 6.92%, indicates a potential shift in investor sentiment. This short-term strength is supported by ris...

Read More

Archit Organosys Q2 FY26: Profitability Under Pressure as Margins Collapse

2025-11-14 09:36:16

Archit Organosys Ltd., a micro-cap commodity chemicals manufacturer, is navigating turbulent waters as its latest quarterly results reveal a sharp deterioration in operational efficiency. The company, with a market capitalisation of ₹92.00 crores, faces mounting challenges despite reporting improved topline growth in recent quarters.

Read More

Is Archit Organosys overvalued or undervalued?

2025-11-14 08:11:46

As of 13 November 2025, Archit Organosys' valuation grade has moved from attractive to fair. The company appears to be overvalued based on its current metrics. Notable ratios include a PE ratio of 147.70, an EV to EBITDA of 18.19, and a PEG ratio of 0.01, which suggests a significant disparity in growth expectations relative to its price. In comparison to peers, Archit Organosys' PE ratio is substantially higher than that of Godrej Industries at 37.09, which is rated attractive, and Aarti Industries at 53.04, also rated fair. The company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -6.00% compared to the Sensex's 8.11%, further reinforcing the notion that Archit Organosys is currently overvalued....

Read More

How has been the historical performance of Archit Organosys?

2025-11-13 23:21:18

Answer: The historical performance of Archit Organosys shows a declining trend in net sales and profits over the past few years. Breakdown: Archit Organosys reported net sales of 113.19 Cr in March 2024, a decrease from 127.78 Cr in March 2023 and 137.90 Cr in March 2022. The total operating income mirrored this decline, remaining at 113.19 Cr in March 2024 compared to 127.78 Cr in the previous year. The total expenditure, excluding depreciation, also decreased to 106.45 Cr in March 2024 from 108.90 Cr in March 2023. Operating profit (PBDIT) fell significantly to 9.18 Cr in March 2024 from 20.74 Cr in March 2023, reflecting a decrease in the operating profit margin from 14.78% to 5.95%. Profit before tax dropped to 4.32 Cr in March 2024, down from 15.36 Cr in March 2023, leading to a profit after tax of 3.28 Cr compared to 11.35 Cr the previous year. The earnings per share also declined to 1.6 in March 202...

Read More

Why is Archit Organosys falling/rising?

2025-11-11 22:04:41

As of 11-Nov, Archit Organosys Ltd's stock price is currently at 45.48, reflecting an increase of 0.2, or 0.44%. The stock has experienced a trend reversal, gaining after two consecutive days of decline. It is trading above its 100-day and 200-day moving averages, but below its 5-day, 20-day, and 50-day moving averages. Additionally, there has been a notable increase in investor participation, with delivery volume rising by 13.73% compared to the 5-day average. However, the stock has shown a negative performance over the past week, month, and year, with declines of 1.32%, 1.83%, and 2.99%, respectively, against a backdrop of positive returns from the benchmark Sensex during the same periods. The positive and negative factors dashboard is unavailable, which limits further insights into specific influences on the stock's recent movements. Broader Market Context: In the short term, Archit Organosys has underp...

Read More

When is the next results date for Archit Organosys?

2025-11-07 23:18:48

The next results date for Archit Organosys is scheduled for 13 November 2025....

Read More

How has been the historical performance of Archit Organosys?

2025-11-03 22:47:04

Answer: The historical performance of Archit Organosys shows a decline in net sales and profits over the years, particularly from March 2022 to March 2024. Breakdown: Archit Organosys reported net sales of 113.19 Cr in March 2024, down from 127.78 Cr in March 2023 and 137.90 Cr in March 2022, indicating a consistent decrease in revenue. The total operating income mirrored this trend, remaining at 113.19 Cr in March 2024, compared to 127.78 Cr in the previous year. The total expenditure, excluding depreciation, also decreased to 106.45 Cr in March 2024 from 108.90 Cr in March 2023. Operating profit (PBDIT) fell significantly to 9.18 Cr in March 2024 from 20.74 Cr in March 2023, reflecting a declining operating profit margin which dropped to 5.95% in March 2024 from 14.78% the previous year. Profit before tax decreased to 4.32 Cr in March 2024, down from 15.36 Cr in March 2023, leading to a profit after tax ...

Read More

Is Archit Organosys overvalued or undervalued?

2025-10-31 08:10:20

As of 30 October 2025, Archit Organosys has moved from a fair to an attractive valuation grade. The company is currently considered overvalued based on its high PE ratio of 150.72, an EV to EBIT of 105.73, and a PEG ratio of 0.01, indicating that the stock price does not align well with its earnings growth potential. In comparison to its peers, Archit Organosys stands out with a significantly higher PE ratio than Godrej Industries, which has a PE of 36.66 and is also rated attractive. Meanwhile, Solar Industries, classified as very expensive, has a PE of 99.55. Despite a recent decline in stock performance relative to the Sensex, with a year-to-date return of -4.08% compared to the Sensex's 8.02%, the valuation metrics suggest that Archit Organosys is not justified at its current price level....

Read More

View All News